PLAU and COVID-19: Therefore, we tested whether the newly identified biomarkers uPA and or uPA-PAI-1 complexes might be novel biomarkers to indicate the worsening of clinical parameters such as the development of ARDS or lymphopenia even in a COVID-19 patient cohort where D-dimer levels were low.